JP7883357B2 - Cpgアンフィフィル及びその使用 - Google Patents
Cpgアンフィフィル及びその使用Info
- Publication number
- JP7883357B2 JP7883357B2 JP2020568945A JP2020568945A JP7883357B2 JP 7883357 B2 JP7883357 B2 JP 7883357B2 JP 2020568945 A JP2020568945 A JP 2020568945A JP 2020568945 A JP2020568945 A JP 2020568945A JP 7883357 B2 JP7883357 B2 JP 7883357B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- protein
- amino acid
- cancer
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20033—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023222587A JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Cpgアンフィフィル及びその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637824P | 2018-03-02 | 2018-03-02 | |
| US62/637,824 | 2018-03-02 | ||
| PCT/US2019/020398 WO2019169328A1 (en) | 2018-03-02 | 2019-03-01 | Cpg amphiphiles and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222587A Division JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Cpgアンフィフィル及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021516991A JP2021516991A (ja) | 2021-07-15 |
| JP2021516991A5 JP2021516991A5 (cg-RX-API-DMAC7.html) | 2022-03-09 |
| JP7883357B2 true JP7883357B2 (ja) | 2026-07-01 |
Family
ID=67805576
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568945A Active JP7883357B2 (ja) | 2018-03-02 | 2019-03-01 | Cpgアンフィフィル及びその使用 |
| JP2023222587A Pending JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Cpgアンフィフィル及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023222587A Pending JP2024045151A (ja) | 2018-03-02 | 2023-12-28 | Cpgアンフィフィル及びその使用 |
Country Status (20)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018201090A1 (en) | 2017-04-28 | 2018-11-01 | Exicure, Inc. | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102787353B1 (ko) | 2018-03-02 | 2025-03-26 | 엘리시오 테라퓨틱스, 인크. | 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도 |
| CA3183735A1 (en) * | 2020-06-26 | 2021-12-30 | Martin P. STEINBUCK | Compositions and methods for inducing an immune response against coronavirus |
| CN116507344A (zh) * | 2020-06-26 | 2023-07-28 | 伊莱西奥治疗有限公司 | 用于诱导针对冠状病毒的免疫应答的组合物和方法 |
| WO2023022973A2 (en) * | 2021-08-16 | 2023-02-23 | Elicio Therapeutics, Inc. | Compositions containing polynucleotide amphiphiles and methods of use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528007A (ja) | 2005-02-05 | 2008-07-31 | 田景武 | 人参の新鮮度を保持する方法 |
| JP2017532373A (ja) | 2014-09-11 | 2017-11-02 | ヴェダントラ ファーマシューティカルズ,インコーポレーテッド | マルチラメラ脂質ベシクル組成物及び使用方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
| AU2001268427B2 (en) | 2000-06-16 | 2007-03-29 | Glaxosmithkline Intellectual Property Limited | Antibodies that immunospecifically bind to blys |
| US8771702B2 (en) * | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
| JPWO2005001116A1 (ja) * | 2003-06-17 | 2006-08-24 | 明治乳業株式会社 | Toll様レセプター強制発現細胞の利用 |
| US9090673B2 (en) | 2003-12-12 | 2015-07-28 | City Of Hope | Synthetic conjugate of CpG DNA and T-help/CTL peptide |
| EP1776105A2 (en) * | 2004-07-18 | 2007-04-25 | Coley Pharmaceutical Group, Ltd | Methods and compositions for inducing innate immune responses |
| MX2009003398A (es) | 2006-09-27 | 2009-08-12 | Coley Pharm Gmbh | Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada. |
| EP2155889A4 (en) * | 2007-05-25 | 2010-06-16 | Centocor Ortho Biotech Inc | TOLL RECEPTOR 3 MODULATORS AND USES THEREOF |
| WO2010071852A2 (en) | 2008-12-19 | 2010-06-24 | University Of Florida Research Foundation, Inc. | Oligonucleotide micelles |
| ES2731343T3 (es) | 2009-05-19 | 2019-11-15 | Univ Miami | Composiciones, kits y métodos para presentación de antígenos in vitro, evaluación de eficacia de vacunas y evaluación de la inmunotoxicidad de productos biológicos y fármacos |
| US20120264810A1 (en) * | 2009-09-22 | 2012-10-18 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| ES2983470T3 (es) | 2010-03-19 | 2024-10-23 | Takeda Pharmaceuticals Co | Inhibidores del TFPI y métodos de uso |
| AU2012209274A1 (en) * | 2011-01-24 | 2013-09-12 | Anterios, Inc. | Nanoparticle compositions, formulations thereof, and uses therefor |
| BR112013030104A8 (pt) | 2011-05-25 | 2021-09-08 | Camurus Ab | Pré-formulação, processo para a formação de uma pré-formulação, método de tratamento cosmético, dispositivo de administração preenchido, e, kit |
| US20150044208A1 (en) | 2011-09-23 | 2015-02-12 | Technophage, Investigaçäo E Desenvolvimento Em Biotecnologia, Sa | Modified Albumin-Binding Domains and Uses Thereof to Improve Pharmacokinetics |
| US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
| KR102109188B1 (ko) | 2013-04-01 | 2020-05-11 | 삼성전자주식회사 | 양이온성 지질을 포함하는 온도민감성 리포좀 및 그의 용도 |
| AR095882A1 (es) * | 2013-04-22 | 2015-11-18 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9 |
| KR102100289B1 (ko) * | 2013-10-24 | 2020-04-13 | 주식회사 다이셀 | 은 나노 입자 함유 분산액의 제조 방법 및 은 나노 입자 함유 분산액 |
| US10940201B2 (en) * | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
| KR20190082850A (ko) | 2016-11-30 | 2019-07-10 | 어드박시스, 인크. | 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법 |
| EP3585428A1 (en) * | 2017-02-23 | 2020-01-01 | Alpha-o Peptides AG | Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids |
| KR102787353B1 (ko) * | 2018-03-02 | 2025-03-26 | 엘리시오 테라퓨틱스, 인크. | 돌연변이 kras 서열 및 지질을 포함하는 화합물 및 이의 용도 |
-
2019
- 2019-03-01 US US16/977,185 patent/US12247052B2/en active Active
- 2019-03-01 UA UAA202006353A patent/UA128863C2/uk unknown
- 2019-03-01 EP EP19761384.7A patent/EP3758712B1/en active Active
- 2019-03-01 KR KR1020207028281A patent/KR102837422B1/ko active Active
- 2019-03-01 CN CN201980028828.9A patent/CN112203663A/zh active Pending
- 2019-03-01 MX MX2020009150A patent/MX2020009150A/es unknown
- 2019-03-01 CA CA3092693A patent/CA3092693A1/en active Pending
- 2019-03-01 CN CN202510413325.0A patent/CN120249290A/zh active Pending
- 2019-03-01 SG SG11202008432XA patent/SG11202008432XA/en unknown
- 2019-03-01 AU AU2019227988A patent/AU2019227988B2/en active Active
- 2019-03-01 PL PL19761384.7T patent/PL3758712T3/pl unknown
- 2019-03-01 MA MA052434A patent/MA52434A/fr unknown
- 2019-03-01 PT PT197613847T patent/PT3758712T/pt unknown
- 2019-03-01 BR BR112020017778-4A patent/BR112020017778A2/pt unknown
- 2019-03-01 WO PCT/US2019/020398 patent/WO2019169328A1/en not_active Ceased
- 2019-03-01 IL IL277101A patent/IL277101B2/en unknown
- 2019-03-01 MY MYPI2020004499A patent/MY209484A/en unknown
- 2019-03-01 DK DK19761384.7T patent/DK3758712T3/da active
- 2019-03-01 JP JP2020568945A patent/JP7883357B2/ja active Active
- 2019-03-01 ES ES19761384T patent/ES3035198T3/es active Active
- 2019-03-01 KR KR1020257023614A patent/KR20250111403A/ko active Pending
-
2020
- 2020-08-31 SA SA520420065A patent/SA520420065B1/ar unknown
-
2023
- 2023-12-28 JP JP2023222587A patent/JP2024045151A/ja active Pending
-
2025
- 2025-01-31 US US19/042,771 patent/US20250171507A1/en not_active Abandoned
- 2025-09-19 US US19/333,784 patent/US20260015390A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008528007A (ja) | 2005-02-05 | 2008-07-31 | 田景武 | 人参の新鮮度を保持する方法 |
| JP2017532373A (ja) | 2014-09-11 | 2017-11-02 | ヴェダントラ ファーマシューティカルズ,インコーポレーテッド | マルチラメラ脂質ベシクル組成物及び使用方法 |
Non-Patent Citations (7)
| Title |
|---|
| ANG, K.K. et al., Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer, N. Engl. J. Med., 2010, Vol.363, pp.24-35, https://doi.org/10.1056/NEJMoa0912217 |
| BODE, C., CpG DNA as a vaccine adjuvant, Expert. Rev. Vaccines, 2011,Vol.10, No.4, pp.499-511, https://doi.org/10.1586/erv.10.174 |
| Chunson Yu et al., Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides., Mol. Pharm., 2017年07月07日, Vol.14, No.8, p.2815-2823, doi: 10.1021/acs.molpharmaceut.7b00335 |
| Hua Li Wang et al., In vitro and in vivo evaluations of human papillomavirus type 16 (HPV16)-derived peptide-loaded dendritic cells (DCs) with a CpG oligodeoxynucleotide (CpG-ODN) adjuvant as tumor vaccines for immunotherapy of cervical cancer, Arch. Gynecol. Obstet., 2013年08月03日, Vol.289, p.155-162, doi: 10.1007/s00404-013-2938-1 |
| LIU, H. et al., Structure-based programming of lymph-node targeting in molecular vaccines, Nature, 2014, Vol.507, pp.519-522, https://doi.org/10.1038/nature12978 |
| 徳丸裕ら, 中咽頭癌におけるヒト乳頭腫ウイルス(HPV)の関与, 耳鼻と臨床, 2010, 56(補1), pp.S21-S24 |
| 郭永梅, CpG-ODN 2006 とB19 genome に共通するssDNA 配列による選択的赤芽球系増殖の抑制, 秋田医学, 2011, 38(2), pp.43-48 |
Also Published As
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200904 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230214 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230512 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230713 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230905 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231229 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260218 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20260310 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20260619 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7883357 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |